Using brain stimulation to reduce cravings in methamphetamine users
The Use of Repetitive Transmagnetic Stimulation to Target Craving in Methamphetamine Use Disorder
NA · Oregon Health and Science University · NCT03470480
This study tests whether a type of brain stimulation can help reduce cravings for methamphetamine in adults who are trying to stay off the drug.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Oregon Health and Science University (other) |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT03470480 on ClinicalTrials.gov |
What this trial studies
This project investigates the effects of high frequency repetitive transmagnetic stimulation (HF-rTMS) on cue-induced cravings in adults with methamphetamine use disorder. Participants who have recently abstained from methamphetamine will be randomly assigned to receive either real or sham rTMS while being exposed to methamphetamine-related or neutral visual cues. The study aims to determine if stimulation of the left dorsolateral prefrontal cortex can effectively reduce cravings for methamphetamine. The outcomes will be measured using validated craving assessments.
Who should consider this trial
Good fit: Ideal candidates are adults with a history of methamphetamine use disorder who have recently abstained from methamphetamine and are motivated to quit.
Not a fit: Patients with significant psychiatric disorders or other substance use disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel non-pharmacological treatment option for individuals struggling with methamphetamine addiction.
How similar studies have performed: While the use of rTMS in addiction treatment is still emerging, preliminary studies have shown promise in reducing cravings for various substances.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Subjects must use at least 0.5 g per day at least 5 days per week and have a minimum 12-month history of METH abuse.
* Subjects must meet DSM V diagnosis for methamphetamine use disorder.
* Subjects must have a minimum 4-week period of detoxification and a desire to stop using methamphetamine.
Exclusion Criteria:
* Present or past history of neurological disorder
* The present history of a DSM IV Axis I or DSM V primary psychiatric disease (apart from MUD and depressive symptoms defined as a Hamilton Depression Scale Score \< 7 ("normal"))
* Scores on the Hamilton Depression Scale \> 8, possibly indicating clinical depression
* No current abuse of drugs other than methamphetamine (except nicotine). Urine-screening tests for psychoactive drugs will be performed to corroborate the lack of drug use.
* Individuals meeting criteria for cannabis use disorder or alcohol use disorder
* Medical illness that can affect brain function
* Past or present history of cardiovascular disease or high blood pressure
* Any history of epilepsy or a known history of seizure disorder
* A history of metal in the head or chest area (except dental fillings or braces)
* Current consumption of psychiatric medication
* Any other medical, neurological or neurosurgical condition that would preclude the administration of repetitive transmagnetic stimulation
Where this trial is running
Portland, Oregon
- Veterans Affairs Portland Health Care System — Portland, Oregon, United States (RECRUITING)
Study contacts
- Study coordinator: Brandon J Cornejo, MD, PhD
- Email: brandon.cornejo@va.gov
- Phone: 503-721-7964
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Methamphetamine Abuse, Substance Use Disorders, Stimulant Dependence, Methamphetamine-dependence, Stimulant Use, Transcranial Magnetic Stimulation